Multicenter Phase II sequential study of S-1/Oxaliplatin (SOX) and Bevacizumab as first line therapy followed by S-1/Irinotecan (IRIS) and Cetuximab as second line in patients with metastatic colorectal cancer. : A SOBIC study

ABSTRACT: Interventions: 1st line SOX+BV 2nd line IRIS+Cmab IRIS+Bmab IRIS Primary outcome(s): Second PFS (progression-free survival) Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2619466 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR